Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Perrigo Third Quarter Net Income Falls on Costs from Deals

By Pharmaceutical Processing | May 7, 2013

Perrigo Co. said Tuesday that its net income slipped 3 percent in the fiscal third quarter on costs related to two acquisitions. But its earnings and revenue missed Wall Street expectations, and its shares fell almost 4 percent.

The healthcare and nutritional products company expanded into animal care in 2012 by buying Sergeant’s Pet Care Products for $285 million. In February it bought Rosemont Pharmaceuticals for $283 million in a deal intended to expand its U.K. business.

Perrigo said its net income fell to $111.9 million, or $1.18 per share, for the three months ended March 30 from $115.7 million, or $1.23 per share.

The company said it earned $1.42 in the latest quarter if one-time items are excluded. Analysts surveyed by FactSet expected higher earnings of $1.44 per share,

Revenue rose 18 percent to $919.8 million from $778 million. Analysts expected $933.3 million in revenue.

Perrigo said most of the revenue gains came from the newly-acquired Sergeant and Rosemont.

The company said revenue from its consumer health care business advanced 20 percent to $536.7 million. Nutritional product revenue rose 13 percent to $133.3 million and prescription drug revenue grew 22 percent to $189.4 million. Drug ingredient revenue increased 11 percent to $41.1 million.

Perrigo maintained its full-year forecast, calling for adjusted net income of $5.53 to $5.73 per share. Analysts expect $5.64 per share on average.

Shares of Perrigo fell $4.43, or 3.7 percent, to $114.41 in afternoon trading.

Related Articles Read More >

Great Point Partners logo.
Great Point Partners acquires majority stake in Eutecma to fuel sustainable cold chain growth
Driving success in fast-paced high-tech pharma construction projects
This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE